Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Characteristics of the LVEF decrease in patients with cardiotoxicity (n = 38)

From: Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients

Cardiotoxicity criteria No. patients % Patients with cardiotoxicity % of patient total
LVEF decrease <50% 7 18,42 7
LVEF decrease >10 points below baseline 16 42,10 16
LVEF decrease > 15 points below baseline 22 57,89 22